secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2023-12-22T23:59:59+00:00
Accession:  0001193125-23-301777
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir discontinues all three Phase 3 posoleucel trials after DSMB futility analyses
--------------------------------------------------------------------------------

- Three Phase 3 trials for prevention, hemorrhagic cystitis, and adenovirus stopped after separate DSMBs deemed each unlikely to meet primary endpoints.
- No safety concerns observed; discontinuation based on pre-planned futility analyses.
- Company to prioritize capital preservation; held $213.3M cash and equivalents as of Sep 30, 2023.
- AlloVir will review strategic alternatives including merger, sale, or licensing of assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523301777/0001193125-23-301777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523301777/d671953d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-301777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer